News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail Digital Asset Direct

HealthBeacon signs "very big deal" in key US market

HealthBeacon PLC

Contact Details Proactive Investors UK +44 20 7989 0813 uk@proactiveinvestors.com

May 30, 2023 11:02 AM Eastern Daylight Time

Video
Article thumbnail News Release

NAVEX Announces AI-Powered Compliance Assistant

NAVEX Global

NAVEX, the leader in integrated risk and compliance management software, today announced NAVEX Compliance Assistant. The initial release of this new AI-powered functionality will offer instant answers to employee questions regarding company policies and procedures delivered in natural language. This functionality makes an organization’s compliance program more accessible and personal for all employees. As part of the NAVEX One GRC Information System, employees interact with NAVEX Compliance Assistant by asking it questions in their own words. The AI-powered Compliance Assistant then searches through a company’s policies and procedures to present a comprehensive answer to the employee’s inquiry. Compliance Assistant applies Large Language Model (LLM) technology to customer-controlled document sets for maximum relevance and accuracy. NAVEX’s secure cloud infrastructure protects document and data privacy. Rich NAVEX Integration Ensures Ease of Use and Data Security The AI-powered NAVEX Compliance Assistant is seamlessly integrated into NAVEX One People Hub, a unified, simplified way for employees to engage with the compliance program. Through People Hub, employees can conveniently report incidents, confirm policy adherence, complete training and disclose information within a user-friendly interface accessible on mobile devices. With the addition of Compliance Assistant, employees, and other authorized parties, can quickly clarify how to follow specific procedures and policies that apply to them. NAVEX Compliance Assistant offers a range of features tailored to meet the needs of organizations of all sizes, including: Intuitive chat interface: Employees can query the system with natural language questions about a policy or procedure of interest and receive prompt, accurate responses. Multilingual access: Users can ask questions and receive answers in 70 languages. Find relevant policies: Employees can easily search for and access relevant, verified policies and procedures, eliminating time-consuming manual searches or the need to reach out across departments to source an answer. Responsive access anywhere: NAVEX Compliance Assistant is accessible via the web and mobile devices, helping employees access critical compliance information from anywhere. Uncompromising privacy and security: NAVEX is committed to safeguarding all data within the systems it manages, including policy and procedure information and employee queries through Compliance Assistant. “Successful organizations turn governance, risk and compliance management into a competitive advantage. It helps prevent mistakes, motivate employees, and promotes confident decision-making,” said Sean Thompson, Chief Executive Officer at NAVEX. “In my years of experience with natural language user interface technology, incorporating it into a GRC program is one of the most exciting applications. Our new AI-enabled Compliance Assistant makes engaging with the compliance program simpler and more intuitive, which in turn makes employees more confident users of the system.” Expert point of view The adoption of AI-powered technologies to facilitate access to compliance-related information can bring great benefits. “Giving employees the ability to quickly and accurately access company policies and procedures fosters a culture of trust and safety with regards to risk mitigation. It also makes the whole process more efficient," said Darren Bradshaw, Chief Audit and Compliance Officer of Stellantis, a multinational automotive company on a journey of transformation into a sustainable mobility tech organization. Stellantis, as a customer of some NAVEX applications, plans to partner with the company to test the usability of this new application. To learn more about the AI-powered NAVEX Compliance Assistant, visit https://www.navex.com/en-us/products/navex-ethics-compliance/ai-employee-compliance-assistant/. Or, read our blog, “ Artificial Intelligence – The Next Frontier of GRC Management ” on Risk & Compliance Matters. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Scott Levesque +1 617-388-5773 scott.levesque@navex.com Company Website https://www.navex.com

May 30, 2023 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

American Diversified Holdings Corporation (OTC: ADHC) In Final Stage Development and Beta Testing of New ECommerce Platform Focused on CBD Products

American Diversified Holdings Corp.

American Diversified Holdings Corporation (OTC: ADHC) is announced today announce that the company is in the final stages of developing a state-of-the-art e-commerce site offering CBD products under ADHC brand UNIVERSAL WELLNESS. ADHC and its operating division UNIVERSAL WELLNESS previously announced a comprehensive alliance with GGII's leading group of a companies in the CBD and Hemp sector. ADHC's agreement with Green Globe Intl Group (OTC: GGII ), Hempaco (NASDAQ: HPCO ) and GGII's operating subsidiary Green Star Labs provides for a broad range of services and interrelated business activity. The GGII/HEMPACCO/GREENSTAR group has entered into this alliance with ADHC and will collaborate as outlined below: Formulation, manufacturing, private label, inventory management, packaging and shipment logistics with be provided by Green Star Labs under the Universal Wellness and Rolls Choice Brand. Jointly design a line of CDB, Dietary Supplements and Cosmetic products to be offered through ADHC' e-commerce beta platform. Introduce and negotiate endorsement agreements with social media influencers and noted HipHop/Rap luminaries. Hempacco currently has relationships deals with Snoop Dogg Brands, rap artist Rick Ross, Hemp Hop Smokables and Cheech and Chong, Hemp Cigarettes. Parties have agreed to a financial partnership including share issuances, line of credit for product inventory, capital formation and addition of future management. Parties have agreed to assess the develop of ADHC existing brand and future products under development, including products sold under the Rolls Choice Brand of cannabis adhesive pens and Universal Wellness lifestyle and CBD products. This alliance and new ECommerce business is set to springboard ADHC'S branded products into the rapidly growing CDB market sector. A recent report by Market Research Future (MRFR) indicated the CDB market is expected to reach over $59 billion by 2030 an 18% CAGR. See: Cannabidiol (CBD) Market Size Worth USD 59.3 Billion "The GGII/HPCO team is a great alliance partner for ADHC, we can now focus on pushing our brands to the forefront of the CBD and Cannabis markets with a manufacturing and brand building partner that is a dream come true for our shareholder," commented ADHC management. About Hempacco (NASDAQ: HPCO ) Hempacco Co., Inc.'s goal is Disrupting Tobacco's™ nearly $1 trillion industry with herb and hemp-based alternatives to nicotine cigarettes by manufacturing and marketing herb, spice, and cannabinoid smokables and rolling paper. Hempacco owns The Real Stuff™ functional hemp cigarette and rolling paper brand. Hempacco's operating segments include: Manufacturing of smokables, hemp rolling paper, and cannabinoid sticks Smokable technology development The Real Stuff™ brand of functional smokables and rolling paper Cheech and Chong Hemp Cigarettes and Hemp Hop Smokables with Rick Ross Snoop Dogg Joint Venture of Hemp-Derived Products Learn more at www.hempacco.com. Order products at www.realstuffsmokables.com. About Green Globe International, Inc. (OTC: GGII ): Green Globe International is a Fast-Moving Consumer Goods incubator and holding company of intellectual property, products, and companies that better people's lives by helping them feel and look better inside and out. Green Globe International (GGII) owns or has interests in several brands and companies including; Green Star Labs, Inc., changing how people feel about themselves inside and out with nutritional supplements, CBD, and beauty products, and hemp CBD cigarette and rolling paper manufacturer Hempacco Co. Inc., (NASDAQ: HPCO) Disrupting Tobacco's™ $1 Trillion tobacco industry, with its subsidiaries and joint ventures including HempBox Vending, Inc. a vending and advertising company, Hempacco Paper Company, Inc., producing The Real Stuff Hemp Smokables and hemp paper smoking products like blunts, tubes, and cones, Cali Vibes, Inc. manufacturing cannabinoid cigarettes, HempHop Smokables, Inc., partnering with music producer and rapper Rick Ross, Cheech and Chong Smokables, Inc. delivering cannabinoid Hemp CBD cigarettes to consumers with Cheech and Chong as partners, StickIt USA, Inc., manufacturing a line of cannabinoid sticks, and HPDG, LLC a partnership with Snoop Dogg to develop hemp-derived consumer goods products. Green Globe International is publicly traded under the ticker symbol (OTC: GGII ). It continues to look for best-in-class companies, products, and patents to create Fast Moving Consumer Goods and channels to sell them, including retail automation and advertising platforms. ABOUT ADHC/UNIVERSAL WELLNESS ADHC is a publicly traded holding company trading under the ticker symbol (OTC: ADHC ). ADHC is currently developing two web-based branded businesses. Universal Wellness (UWS) is a wellness and lifestyle e-commerce site focused on providing innovative products, news, and the latest healthcare developments Shares Outstanding: 866 million Shares Restricted: 301 million Shares in the Float: 504 million Investor Contact: Andrew Birnbaum Chairman/CEO CEO@ADHCINVESTOR.com TWITTER: @ADHCManagement. This Twitter page is the only official Twitter page for ADHC. Information contained herein includes forward-looking statements. SAFE HARBOR These statements relate to future events or future financial performance, involving known and unknown risks and uncertainties that may cause our actual results to be materially different to performance or achievements expressed. You should not place undue reliance on these statements, since they involve known and unknown risks. Any forward-looking statements reflect the current view with respect to future events and subject to uncertainties. Contact Details Andrew Birnbaum, Chairman/CEO CEO@ADHCINVESTOR.com

May 30, 2023 06:30 AM Eastern Daylight Time

Article thumbnail News Release

NovaBay Pharmaceuticals looking to grow its three verticals of eye, skin, and wound care in 2023

NovaBay Pharmaceuticals

NovaBay Pharmaceuticals CEO Justin Hall joined Steve Darling from Proactive to talk more about the company that has developed scientifically proven eye care, skin care and wound care products. The company's top product is Avenova, which has proven in laboratory testing to have broad antimicrobial properties as it removes foreign material and debris from the skin around the eye, including the eyelid. Hall telling Proactive the company acquired DermaDoctor, a skincare brand, in 2021. He emphasizes that all their products are doctor-recommended and clinically developed to address specific needs. NovaBay aims to excel in all three verticals, including wound care, and expects continued growth and success. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

May 29, 2023 01:52 PM Eastern Daylight Time

Video
Article thumbnail News Release

Valeo Pharma 2Q results show same form as 1Q with guidance revealing record quarterly revenue

Valeo Pharma Inc.

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share guidance for the company’s second-quarter that reveal it is heading for the sixth straight quarter of record revenue. The company said it expects 2Q revenue to exceed $13.5 million while its adjusted underlying (EBITDA) loss will decrease to below $2 million as the company heads to profitability. Saviuk told Proactive the number continues to be driven by Asthma medications ENERZAIR and ATECTURA which saw quarterly revenues grow 270% over this time last year. In fact, the total number of prescribing physicians also grew and is now expected to exceeds 2,000. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

May 29, 2023 12:57 PM Eastern Daylight Time

Video
Article thumbnail Digital Asset Direct

Creo Medical Group "really pleased" with first human trial of lung lesion treatment

Creo Medical Group PLC

Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 26, 2023 11:07 AM Eastern Daylight Time

Video
Article thumbnail News Release

UAT Group Strategic Partner Next Casting Receives Patent

Umbra Applied Technologies Group, Inc.

Umbra Applied Technologies Group, Inc. (UAT Group) (OTC: UATG ) - UAT Group strategic partner Next Casting Technologies has been issued a patent for technology it developed for use in its advanced SmartCast, IntelliBrace and BioSplint products. Filed in December of 2017, this patent was one of four patents that had been pending. The Company anticipates remaining patents being approved over the next ten to twelve months. Next Casting Technologies (NCT) has begun the process of commercializing proprietary technologies which will positively impact people’s lives and increase value through a unique and diverse product line. The SmartCast Application allows the casting technician to slip the SmartCast around the affected limb and position to fit by using a simple “mold and hold” technique. Lastly, the cast is activated by pressing the button to initiate the curing process. Within 4 minutes that cast is hardened, fixed in place and is not dependent on the technician’s artistry, or lack thereof. The results are a predictable standard of care across the patient spectrum. The end result is a completely waterproof, antimicrobial, orthopedic cast, that is time saving for clinicians and a superior standard of care for patients. UAT Group’s Chief Executive Officer Alex Umbra, stated, “This marks a significant step forward for NCT. Having the appropriate measures in place to protect intellectual property enables the Company to begin evaluating production schedules, supply chain resources and fulfillment execution strategies. I look forward to working with the NCT team in the near-term future as they begin their ramp up.” UAT Group has a 26% equity interest in NCT. For more information about NextCast go here: https://nextorthocast.com/ For more information about UAT go here: http://umbraappliedtechnologies.com/ About Umbra Applied Technologies Group, Inc. The firm is located in Tampa, Florida and focuses on advanced technologies across many disciplines. UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UAT Group subsidiaries. For more information, visit: www.uatgroup.com Investor and Media Contact: info@uatgroup.com NEITHER THE SECURITIES EXCHANGE COMMISSION NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. Forward-Looking Information This news release may include "forward-looking statements" including forecasts, estimates, expectations, and objectives for future operations including but not limited to its ability to conclude a business combination with a third party, sale of assets, return of capital or initial public offering and a secondary listing on the OTC as a result of aforementioned and its ability to fund the exploration of its assets through the raising of equity or debt capital or through funding by a joint venture partner that are subject to a number of assumptions, risks, and uncertainties, many of which are beyond the control of Umbra Applied Technologies Group including but not limited to capital markets and securities risks and continued development success on technology. There can be and are no actual or implied guarantees that any of the above activities will be completed or completed on terms acceptable to the Company and its shareholders or approved by any regulatory authority having jurisdiction. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Umbra Applied Technologies Group does not assume the obligation to update any forward-looking statement, except as required by applicable law. Contact Details UAT Group info@uatgroup.com

May 26, 2023 08:00 AM Eastern Daylight Time

Article thumbnail Digital Asset Direct

Poolbeg Pharma's new NED looking at "new opportunities" for the business

Poolbeg Pharma PLC

Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 26, 2023 07:32 AM Eastern Daylight Time

Video
Article thumbnail News Release

M2Bio Sciences Division M2Biome Cardiometabolic Health Launches Website

Institute of Biomedical Research Corp.

Institute of Biomedical Research (OTC: MRES) ("M2Bio Sciences'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update: M2Biome, a division of M2Bio Sciences, is pleased to announce the launch of its website. The website has been set up to serve healthcare professionals and health consumers alike. Sections include a health blog, called ‘Digestible Facts’, educational resources, recipes, and more. One key feature of the website includes a diabetes screening tool on the home page, which will notify people of their risk of having undiagnosed type 2 diabetes (T2DM) and prompt them to undergo further tests. This is also a valuable tool for highlighting the lifestyle changes that are needed to reduce the risk of developing T2DM and other non-communicable diseases that have similar underlying pathophysiology. Part of the M2Biome mission is to provide education on health and nutrition, and create awareness of the risk of disease. “The prevalence of undiagnosed diabetes in South Africa is estimated to be in the region of 45%. Unfortunately, many people are only diagnosed once they have developed complications, which has a huge impact on the quality of life and the cost of managing these individuals. As type 2 diabetes is largely preventable and manageable, I am passionate about creating awareness of risk. I am currently working on further validating the African Diabetes Risk Score to make it more generalizable in the South African population. ”, says Nicola Royce, Managing Director of M2Biome. The recipe section will be the ultimate user-friendly guide to very practical and easy-to-prepare healthy dishes. Each recipe will also serve as an opportunity to educate on the nutritional content of the dish. You will also learn how to make use of simple cooking methods to get the most out of the least ingredients. The recipes are divided into breakfast, lunch, dinner, dessert, snacks, condiments, and drinks for easy access to your needs. Icons have been developed to guide you in meeting your special dietary requirements with confidence. "Food should be fun, functional, and user-friendly. If you cannot make it, you cannot eat it. It is unacceptable for good produce to go to waste because it is too difficult to make the most of it. Never should any ingredient be used or abused to end up being unhealthy. Cooking should be easy and done in such a way that the end result is multi-beneficial. ", says Wilna Eksteen, Cardiometabolic Product Developer. M2Biome is also developing a Registered Dietitian database for health consumers to seek individualized treatment. While there are some basic principles when it comes to nutrition, there is no ‘blanket’ approach when applying medical nutrition therapy for various conditions. It is important for people to consult a Registered Dietitian to receive an individualized and tailored approach that takes religious requirements, life cycle stage, and dietary requirements and preferences into account. ‘’In line with an individualized approach, M2Biome will be incorporating Artificial Intelligence and Machine Learning for better patient outcomes. Machine learning takes large amounts of data to uncover patterns and insights related to dietary choices, health outcomes, and nutritional needs. Leveraging machine learning algorithms assists with developing personalised nutrition recommendations based on individual factors such as age, gender, activity level, and health conditions, leading to more tailored and effective dietary interventions. This will all be incorporated into an interactive model that assists individuals with ‘health nudges’ by generating meal plans, recipes to go with these meal plans, and even recommendations of where and what to eat, based on their requirements. Individuals can insert their daily activities, which will be documented and made available to their healthcare practitioners. Any health developments are recorded, which assists with adjusting recommendations and advising on any drug and nutrient interactions that should be remedied. This is all really the tip of the iceberg, and the sky appears to be the limit with all of the ‘smart’ technology we have in our lives today and how it can be used to connect the dots to help us lead healthier lives. This new interactive platform is going to be epic!’’ says Jeff Robinson, M2Bio Sciences CEO. About Institute of Biomedical Research Corp./ DBA M2Bio Sciences Institute of Biomedical Research Corp, is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES". Contact: Website: www.m2biome.com E-mail: m2biome@m2bio.co Phone: +27 72 333 2148 Visit us on social media: Facebook Twitter LinkedIn Instagram Forward-Looking Statements: Safe Harbour Statement: In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements. Contact Details Institute of Biomedical Research Corp. m2biome@m2bio.co Company Website http://www.m2biome.com/

May 25, 2023 08:30 AM Eastern Daylight Time

1 ... 100101102103104 ... 282